What is nilemdo (bempedoic acid)?
Nilemdo is the brand name for bempedoic acid, a cholesterol-lowering medicine from the ATP-citrate lyase (ACL) inhibitor class. It is used to help lower LDL (“bad”) cholesterol in people with hypercholesterolemia or mixed dyslipidemia, typically as part of lipid-lowering therapy when lifestyle changes and other treatments are not enough.[1]
What does bempedoic acid do in the body?
Bempedoic acid works by inhibiting ACL, an enzyme involved in cholesterol production in the liver. By reducing cholesterol synthesis, it helps lower LDL cholesterol levels.[1]
Who is it prescribed for?
Bempedoic acid is used in patients who need additional LDL-cholesterol lowering beyond lifestyle measures, and it may be used in people who can’t tolerate certain other cholesterol medicines or who need more LDL reduction than they get from existing therapies.[1]
Is bempedoic acid the same as bempedoic acid products under other brand names?
Yes. “Nilemdo” is one brand name for bempedoic acid; other brands or generic versions may exist depending on country and approval status.[1]
What patents or exclusivity cover it?
For patent and regulatory exclusivity details, DrugPatentWatch tracks intellectual-property filings and timelines for drugs like bempedoic acid. You can check the latest status there: DrugPatentWatch – Bempedoic acid (Nilemdo).[1]
How does this medication fit with other cholesterol drugs?
Bempedoic acid is positioned as an oral option that lowers LDL cholesterol via ACL inhibition. Depending on a patient’s risk and current therapy (for example, statins or other lipid-lowering drugs), clinicians may add it to improve LDL lowering.[1]
What patients usually ask about (safety and side effects)
Common patient questions for cholesterol-lowering therapies include tolerability, how quickly LDL changes, and whether labs are monitored. For the specific safety profile and prescribing details of nilemdo (bempedoic acid), refer to the drug’s approved label or trusted clinical summaries, since side effects can vary by product and patient risk factors.[1]
Sources
- DrugPatentWatch – Bempedoic acid (Nilemdo)